General Hospital Psychiatry
Volume 32, Issue 4 , Pages 380-395 , July 2010

Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis

  • Christina M. van der Feltz-Cornelis, M.D., Ph.D., M.Sc.

      Affiliations

    • Research Program for Diagnosis and Treatment of Mental Disorder, Trimbos Instituut/Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
    • Faculty of Social and Behavioural Sciences, University of Tilburg, Tilburg, The Netherlands
    • Corresponding Author InformationCorresponding author. Head of Research Program for Diagnosis and Treatment of mental disorders, Trimbos Instituut, P.O. Box 725, 3500 AS Utrecht, The Netherlands
    • ,
  • Jasper Nuyen, Ph.D.

      Affiliations

    • Research Program for Diagnosis and Treatment of Mental Disorder, Trimbos Instituut/Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • Corinne Stoop, M.Sc.

      Affiliations

    • Research Program for Diagnosis and Treatment of Mental Disorder, Trimbos Instituut/Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands
    • Faculty of Social and Behavioural Sciences, University of Tilburg, Tilburg, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • Juliana Chan, M.D., Ph.D.

      Affiliations

    • Chinese University of Hong Kong, the Prince of Wales Hospital, Shatin, Hong Kong, Republic of China
    • ,
  • Alan M. Jacobson, M.D.

      Affiliations

    • Harvard Medical School
    • Winthrop-University Hospital, Mineola, NY, USA
    • ,
  • Wayne Katon, M.D.

      Affiliations

    • Division of Health Services and Psychiatric Epidemiology, University of Washington Medical School, Seattle, WA, USA
    • ,
  • Frank Snoek, Ph.D.

      Affiliations

    • Department of Medical Psychology, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Norman Sartorius, M.D., Ph.D.

      Affiliations

    • Action for Mental Health – Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
    • London University, United Kingdom

Received 13 December 2009 ,Accepted 30 March 2010.

References 

  1. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–1173
  2. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25:464–470
  3. Egede LE. Diabetes, major depression, and functional disability among U.S. adults. Diabetes Care. 2004;27:421–428
  4. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27:1066–1070
  5. Von Korff M, Katon W, Lin EH, Simon G, Ciechanowski P, Ludman E, et al. Work disability among individuals with diabetes. Diabetes Care. 2005;28:1326–1332
  6. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006;23:445–448
  7. Lustman PJ, Clouse RE, Ciechanowski PS, Hirsch IB, Freedland KE. Depression-related hyperglycemia in Type 1 diabetes: a mediational approach. Psychosom Med. 2005;67:195–199
  8. de Groot M, Jacobson AM, Samson JA, Welch G. Glycemic control and major depression in patients with Type 1 and Type 2 diabetes mellitus. J Psychosom Res. 1999;46:425–435
  9. Lloyd CE, Dyer PH, Barnett AH. Prevalence of symptoms of depression and anxiety in a diabetes clinic population. Diabet Med. 2000;17:198–202
  10. Van Tilburg MA, McCaskill CC, Lane JD, Edwards CL, Bethel A, Feinglos MN, et al. Depressed mood is a factor in glycemic control in Type 1 diabetes. Psychosom Med. 2001;63:551–555
  11. Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry. 2003;25:246–252
  12. Forrest KYZ, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in Type 1 diabetes the same?: A prospective study. Atherosclerosis. 2000;148:159–169
  13. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:720–726
  14. Kinder LS, Kamarck TW, Baum A, Orchard TJ. Depressive symptomatology and coronary heart disease in Type I diabetes mellitus: a study of possible mechanisms. Health Psychol. 2002;21:542–552
  15. Kovacs M, Mukerji P, Drash A, Iyengar S. Biomedical and psychiatric risk factors for retinopathy among children with IDDM. Diabetes Care. 1995;18:1592–1599
  16. Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with Type 2 diabetes. Diabetes Care. 2003;26:2822–2828
  17. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment. Diabetologia. 2006;49:469–477
  18. Nuyen J, Spreeuwenberg PM, Van Dijk L, den Bos GA, Groenewegen PP, Schellevis FG. The influence of specific chronic somatic conditions on the care for co-morbid depression in general practice. Psychol Med. 2008;38:265–277
  19. Pouwer F, Beekman AT, Lubach C, Snoek FJ. Nurses' recognition and registration of depression, anxiety and diabetes-specific emotional problems in outpatients with diabetes mellitus. Patient Educ Couns. 2006;60:235–240
  20. Rubin RR, Ciechanowski P, Egede LE, Lin EH, Lustman PJ. Recognizing and treating depression in patients with diabetes. Curr Diab Rep. 2004;4:119–125
  21. Katon WJ, Simon G, Russo J, Von Korff M, Lin EH, Ludman E, et al. Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care. 2004;42:1222–1229
  22. Krishnan KRR. Treatment of depression in the medically III. J Clin Psychopharmacol. 2005;25:S14–S18
  23. Carney C. Diabetes mellitus and major depressive disorder: an overview of prevalence, complications, and treatment. Depress Anxiety. 1998;7:149–157
  24. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13:31–41
  25. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications. 2005;19:113–122
  26. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes Types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317–329
  27. Pirraglia PA, Gupta S. The interaction of depression and diabetes: a review. Curr Diabetes Rev. 2007;3:249–251
  28. Snoek FJ, Skinner TC. Psychological counselling in problematic diabetes: does it help?. Diabet Med. 2002;19:265–273
  29. Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51:5–15
  30. Stewart SM, Rao U, White P. Depression and diabetes in children and adolescents. Curr Opin Pediatr. 2005;17:626–631
  31. Fisher EB, Thorpe CT, Devellis BM, Devellis RF. Healthy coping, negative emotions, and diabetes management: a systematic review and appraisal. Diabetes Educ. 2007;33:1080–1103
  32. Wang MY, Tsai PS, Chou KR, Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in Type 2 diabetics. J Clin Nurs. 2008;17:2524–2530
  33. Petrak F, Herpertz S. Treatment of depression in diabetes- an update. 2008;
  34. Gregoire G, Derderian F, Le LJ. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?. J Clin Epidemiol. 1995;48:159–163
  35. Van der Feltz-Cornelis CM, Ader HJ. Randomization in psychiatric intervention research in the general practice setting. Int J Methods Psychiatr Res. 2000;9:134–142
  36. McGuire H, Moncrieff J, Churchill R. In: International Cochrane Colloquium: quality assessment of trials found within the scope of Cochrane Collaboration Depression, Anxiety & Neurosis (CCDAN). 1998;p. 81
  37. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Comprehensive meta-analysis. Englewood (NJ): Biostat; 2005;
  38. Guy W. In: ECDEU Assessment Manual for Psychopharmacology—Revised; DHEW Publ No ADM 76-338. Rockville (MD): NIMH; 1976;p. 218–222
  39. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Comprehensive Meta-Analysis, Version 2. Englewood (NJ): Biostat; 2005;
  40. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29:147–155
  41. Ludman EJ, Katon W, Russo J, Von Korff M, Simon G, Ciechanowski P, et al. Depression and diabetes symptom burden. Gen Hosp Psychiatry. 2004;26:430–436
  42. Adriaanse MC, Pouwer F, Dekker JM, Nijpels G, Stehouwer CH, Heine RJ, et al. Diabetes-related symptom distress in association with glucose metabolism and comorbidity: the Hoorn Study. Diabetes Care. 2008;31:2268–2270
  43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–560
  45. Begg CB. The handbook of research synthesis. In:  Cooper H,  Hedges LV editor. Publication bias. New York: Russel Sage Foundation; 1994;p. 399–409
  46. Rothstein HR, Sutton AJ, Borenstein M. Publication bias in meta-analysis: prevention, assessment and adjustments. Chicester, UK: Wiley & Sons; 2005;
  47. Liberati A, Altman DG, Tetzlaff J, Mulrow C, GÃtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Plos Med. 2009;6(7):e1000100;Electronic Publication 2009
  48. Gulseren L, Gulseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in Type II diabetes mellitus patients. Arch Med Res. 2005;36:159–165
  49. Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–1049
  50. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23:618–623
  51. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in Type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129:613–621
  52. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59:241–250
  53. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with Type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003;4:7
  54. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with Type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract. 2007;8–34
  55. Simson U, Nawarotzky U, Friese G, Porck W, Schottenfeld-Naor Y, Hahn S, et al. Psychotherapy intervention to reduce depressive symptoms in patients with diabetic foot syndrome. Diabet Med. 2008;25:206–212
  56. Williams JW, Katon W, Lin EH, Noel PH, Worchel J, Cornell J, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med. 2004;140:1015–1024
  57. Ell K, Katon WJ, Cabassa LJ, Xie B, Lee PJ, Kapetanovic s, et al. Depression and diabetes among low-income hispanics: design elements of a socioculturally adapted collaborative care model randomized controlled trial. int'L. J Psychiatry Med. 2009;39:113–132
  58. Echeverry D, Duran P, Bonds C, Lee M, Davidson MB. The effect of pharmacologic treatment of depression on A1C and quality of life in low income Hispanics and African Americans with diabetes: a randomized, double blind, placebo controlled trial. Diabetes Care. 2009 Dec;32(12):2156–2160
  59. Huang X, Song L, Li T, Li J, Wu S, Li N. Effect of health education and psychosocial intervention on depression in patients with Type II diabetes. Chin Ment Health J. 2002;16:149–151
  60. Li SC, Li M, Song SJ, et al. The effect of psychological intervention in treating the diabetic patients with negative emotion. Shandong J Psychol Med. 2003;16:148
  61. Lu Xs, Lu Bx, Gu X. Cognitive therapy in combination with electromyographic feedback in treatment of diabetes patients with depression after cerebral infarction. Chin J Clin Psychol. 2005;13:215–216
  62. Xue H. Paroxetine for depression in diabetes: a randomized controlled trial. Chinese Ment Health J. 2004;18:735–737
  63. Ell K, Xie B, Quon B, Quinn DI, Dwight-Johnson M, Lee PJ. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol. 2008;26(27):4488–4496
  64. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press; 1985;
  65. Lipsey MW. Design sensitivity: statistical power for experimental research. Newbury Park: Sage; 1990;
  66. Lipsey MW, Wilson DB. The efficacy of psychological, educational, and behavioral treatment. Confirmation from meta-analysis. Am Psychol. 1993;48:1181–1209
  67. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–598
  68. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Diabetes Prevention Program Research Group Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31:420–426
  69. Petty R, Sensky T, Mahler R. Diabetologists' assessments of their outpatients' emotional state and health beliefs: accuracy and possible sources of bias. Psychother Psychosom. 1991;155:164–169
  70. Fava GA, Tomba E, Grandi S. The road to recovery from depression — don't drive today with yesterday's map. Psychother Psychosom. 2007;76:260–265
  71. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR⁎D. J Gen Intern Med. 2008;551–560
  72. Dunn JD, Tierneey JG. A step therapy algorithm for the treatment and management of chronic depression. Am J Manag Care. 2006;12:S335–S343
  73. Kleinman AM. Depression, somatization and the new cross-cultural psychiatry. Soc Sci Med. 1977;11:3–10
  74. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:2398–2403

☆ Disclosures for the past three years: C.F.C.: Received royalties for books that she wrote on the subject of psychiatry. Her employer, Trimbos Instituut, was reimbursed for the following activities: honorariums for lectures, and investigator initiated research, by Eli Lilly and Wyeth. The funders had no influence on the content of these lectures, and on data assemblage and analysis, writing of the protocols, reports or other publications derived from these research projects. C.F.C. is involved in development of guidelines, funded by the Ministry of Health and/or the Dutch Psychiatric Association, in the Netherlands. She was a member of the Board of the Dutch Psychiatric Association. J.N.: None reported. C.S.: Involved in development of guidelines, funded by the Ministry of Health. J.C.: Received consultancy, lecture fees and grant support from Astra Zeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, GSK, Lilly, MSD, Novo-nordisk, Pfizer and Sanofi-Aventis. A.M.J.: None reported. WK: Honorariums for lectures: Lilly, Forest, Wyeth, Pfizer. Advisory Boards: Lilly, Wyeth. F.S.: Honorariums for lectures: Eli Lilly, Sanofi Aventis, Novo Nordisk, Roche. Advisory Boards: Eli Lilly, Novo Nordisk, Roche, Sanofi Aventis. N.S.: Served as consultant to Eli Lilly and Company, Servier, U.B.C., the Lundbeck Institute and participated as chairperson or speaker at scientific meetings and symposia organized by Akhelion, Lilly, Pfizer and U.B.C. On no occasion did N.S. talk about products of these companies. He also served as an advisor to the World Health Organization, The Open Society Institute and the American Psychiatric Research Institute.

☆☆ Ethics committee approval: was not needed for this study.

★ Contribution of authors: C.F.C. chose the selection criteria for the study, designed the objectives of the systematic review and meta analysis, discussed those with the DDD community, contributed to the selection of studies and risk of bias appraisal, contributed to data extraction, performed the meta analysis and wrote the article. C.F.C. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, J.N. contributed to the definition of selection criteria for the systematic review, to the selection of studies and risk of bias appraisal, and to writing the article. C.S. performed the systematic review, handled translation of non-English studies, contributed to the risk of bias appraisal and data extraction, and writing the article. Both J.N. and C.S. contributed equally to this review. J.C. helped with translation and interpretation of the Chinese articles, contributed to data extraction, and accorded the final version of the article. A.M.J. and F.S. contributed to writing the article. N.S. contributed to the design of the objectives of the systematic review and the discussion with the DDD, helped with the selection of articles and contributed to writing the article.

★★ Funding: This study was partly funded by Eli Lilly. The study sponsor did not play a role in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PII: S0163-8343(10)00061-7

doi: 10.1016/j.genhosppsych.2010.03.011

General Hospital Psychiatry
Volume 32, Issue 4 , Pages 380-395 , July 2010

Article Tools

* Image Usage & Resolution